Healthcare Industry News: Magnetoencephalography
News Release - May 8, 2006
VSM reports progress on using MEG for diagnosing Alzheimer's and Parkinson'sVANCOUVER, May 8 (Healthcare Sales & Marketing Network) - VSM MedTech Ltd. (TSX:VSM ), a world leader in the emerging clinical market for Magnetoencephalography (MEG) functional brain imaging systems, reported on progress in the diagnosis of Alzheimer's disease and Parkinson's disease by researchers at VU University Medical Center in Amsterdam, Netherlands.
Preliminary results indicate that a software platform and protocols involving a five to ten minute test developed by the MEG Center at VU University Medical Center may be effective for identifying disruption in intra- and inter-hemispheric synchronization in patients with these two cognitive disorders. The results were discussed publicly in a recent VSM-supported Amsterdam symposium on "New Approaches to Clinical Use of MEG."
"Identifying this disruption in synchronization could represent a quick, inexpensive and objective marker for these disorders,' said Dr. Mark Gelfer, VSM's Medical Director. "Such markers are not currently available with other diagnostic methods."
VU University Medical Center is submitting peer-reviewed papers on its Alzheimer's and Parkinson's disease progress to journals for publication this year. In addition, the Parkinson's disease results involving synchronization disruption will be presented in June at an international congress on Parkinson's disease in Amsterdam.
The preliminary results regarding the software platform and protocols for Alzheimer's disease and Parkinson's disease involved tests on an aggregate of 75 patients and healthy controls. The MEG system used was VSM's 151-channel CTF MEG(TM) device, purchased by VU in 1997. Larger studies are required to confirm the findings. VSM will endeavour to assist with a broad confirmation of the results because of the potential value for the medical community and for future sales of MEG systems.
Professor Dr. C.J. Stam, Head of Clinical Neurophysiology at VU University Medical Center and Head of its MEG center, said MEG is now being added to a large ongoing Dutch study of 400 people that began in 1984, when the subjects were in high school. "We think MEG is rapidly becoming a key tool for diagnosing and predicting cognitive and other brain disorders in the future," said Dr. Stam.
VU University Medical Center has previously published MEG studies on Alzheimer's disease in 2000 and 2002. In addition, earlier this year VU University Medical Center published two MEG studies on cognitive disorders, one involving brain tumor patients and the other involving multiple sclerosis patients.
About VU University Medical Center
The VU University Medical Center's tertiary clinical care and tertiary referral-centre care functions play a leading role in the Dutch health service. Activities often involve unique diagnosis and treatment, as well as specialized research. The VU University Medical Center also functions as a hospital, with an outpatients department, where patients can obtain normal specialized care. The other principal tasks of the VU University Medical Center are scientific research, academic programs and training. Further information abut VU is available at www.vumc.nl/english/ongoing/index.html . Information about VU's MEG center, including the symposium program, is available at www.vumc.nl/MEG/ .
VSM MedTech develops, manufactures and markets medical devices for the diagnosis and treatment of neurological disorders and cardiovascular diseases. Targeting significant global market opportunities, VSM equips healthcare providers with noninvasive technology that improves the standard of patient care.
This document may contain forward-looking statements, relating to the Company's operations or to the environment in which it operates, which are based on VSM's operations, estimates, forecasts and projections. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict, or are beyond VSM's control. A number of important factors, including those set forth in other public filings, could cause actual outcomes and results to differ materially from those expressed in these forward-looking statements. Consequently, readers should not place any undue reliance on such forward-looking statements. In addition, these forward-looking statements relate to the date on which they are made. VSM disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: VSM MedTech
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.